Antagonists of TNF action: clinical experience and new developments

Bibliography

• Wong M, Ziring D, Korin Y, et al. TNFα blockade in human diseases: mechanisms and future directions. Clin Immunol 2008;126:121-36
   PubMed Web of Science ®Google Scholar
• Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001;104:487-501
   PubMed Web of Science ®Google Scholar
• Grell M, Douni E, Walant H, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995;83:793-802
   PubMed Web of Science ®Google Scholar
• Bryde S, Grunwald I, Hammer A, et al. Tumor necrosis factor (TNF)-functionalized nanostructured particles for the stimulation of membrane TNF-specific cell responses. Bioconjug Chem 2005;16:1459-67
   PubMed Web of Science ®Google Scholar
• Chan FK. The pre-ligand binding assembly domain: a potential target of inhibition of tumour necrosis factor receptor function. Ann Rheum Dis 2000;59(Suppl 1):50-3
   Web of Science ®Google Scholar
• Banner DW, D'Arcy A, Janes W, et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: implications for TNF receptor activation. Cell 1993;73:431-45
   PubMed Web of Science ®Google Scholar
• Friedmann E, Hauben E, Maylandt K, et al. SPPL2a and SPPL2b promote intramembrane proteolysis of TNFα in activated dendritic cells to trigger IL-12 production. Nat Cell Biol 2006;8:843-8
   PubMed Web of Science ®Google Scholar
• Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003;10:45-65
   PubMed Web of Science ®Google Scholar
• Lamkanfi M, Festjens N, Declercq W, et al. Caspases in cell survival, proliferation and differentiation. Cell Death Differ 2007;14:44-55
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay D, Riezman H. Proteasome-independent functions of ubiquitin in endocytosis and signaling. Science 2007;315:201-5
   PubMed Web of Science ®Google Scholar
• Manning BD, Cantley LC. AKT/PKB singnaling: navigating downstream. Cell 2007;129:1261-74
   PubMed Web of Science ®Google Scholar
• Liesz A, Suri-Payer E, Veltkamp C, et al. Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. Nat Med 2009 [Epub ahead of print]
   PubMedGoogle Scholar
• Bayry J, Sibéril S, Triebel F, et al. Rescuing CD4+CD25+ regulatory T-cell functions in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy. Drug Discov Today 2007;12:548-52
   PubMed Web of Science ®Google Scholar
• Vassalli P. The pathophysiology of tumor necrosis factor. Annu Rev Immunol 1992;10:411-52
   PubMed Web of Science ®Google Scholar
• Ghezzi P, Cerami A. Tumor necrosis factor as a pharmacological target. Mol Biotechnol 2005;31:239-44
   PubMed Web of Science ®Google Scholar
• Kollias G. TNF pathophysiology in murine models of chronic inflammation and autoimmunity. Semin Arthritis Rheum 2005;34(Suppl 1):3-6
   PubMed Web of Science ®Google Scholar
• Kimberley FC, Lobito AA, Siegel RM, et al. Falling into TRAPS - receptor misfolding in the TNF receptor 1-associated periodic fever syndrome. Arthritis Res Ther 2007;9:217
   PubMed Web of Science ®Google Scholar
• Arnett HA, Mason J, Marino M, et al. TNFα promotes proliferation of oligodendrocyte progentiors and remyelination. Nat Neurosci 2001;4:1116-22
   PubMed Web of Science ®Google Scholar
• Palladino MA, Bahjat FR, Theodorakis EA, et al. Anti-TNF-α therapies: the next generation. Nat Rec Drug Discov 2003;2:736-46
   PubMed Web of Science ®Google Scholar
• Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244-79
   PubMed Web of Science ®Google Scholar
• Lugering A, Schmidt M, Lugering N. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001;121:1145-57
   PubMed Web of Science ®Google Scholar
• Shen C, Assche GV, Colpaert S. Adalimumab induces apoptosis of human monocytes: a comparative studiy with infliximab and etanercept. Aliment Pharmacol Ther 2005;21:251-8
   PubMed Web of Science ®Google Scholar
• Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor α agents. Inflamm Bowel Dis 2007;13:1323-32
   PubMed Web of Science ®Google Scholar
• Kirchner S, Holler E, Haffner S. Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes. Cytokine 2004;28:67-74
   PubMed Web of Science ®Google Scholar
• Loetscher H, Gentz R, Zulauf M, et al. Recombinant 55-kDa tumor necrosis factor (TNF) receptor. Stoichiometry of binding to TNFα and TNFβ and inhibition of TNF activity. J Biol Chem 1991;266:18324-9
   PubMed Web of Science ®Google Scholar
• Haak-Frenscho M, Marsters SA, Mordenti J, et al. Inhibition of TNF by a TNF receptor immunoadhesin. Comparison to an anti-TNF monoclonal antibody. J Immunol 1994;152:1347-53
   PubMed Web of Science ®Google Scholar
• Ducharme E, Weinberg JM. Etanercept. Expert Opin Biol Ther 2008;8:491-502
   PubMed Web of Science ®Google Scholar
• Mohan AK, Coté TR, Block JA. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 2004;39:295-9
   PubMed Web of Science ®Google Scholar
• Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Prac Rheum 2006;2:602-10
   PubMedGoogle Scholar
• Bongartz T, Sutton AJ, Sweeting MJ. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. JAMA 2006;19:2275-482
   Web of Science ®Google Scholar
• Christen U, Thuerkauf R, Stevens R, et al. Immune response to a recombinant human TNFR55-IgG1 fusion protein: auto-antibodies in rheumatoid arthritis (RA) and multiple sclerosis (MS) patients have neither neutralizing nor agonist activities. Hum Immunol 1999;60:774-90
   PubMed Web of Science ®Google Scholar
• Abraham E, Laterre PF, Garbino J, et al. Lenercept (p55 tumor necrosis factor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med 2001;29:503-10
   PubMed Web of Science ®Google Scholar
• Rau R, Sander O, van Riel P, et al. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis. J Rheumatol 2003;30:680-90
   PubMed Web of Science ®Google Scholar
• Anonymous. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The lenercept multiple sclerosis study group and the University of British Columbia MS/MRI analysis group. Neurology 1999;53:457-65
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Lemmens L, van Assche G, et al. Treatment of active Crohn's disease with oncercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment Pharmacol Ther 2003;17:185-92
   PubMed Web of Science ®Google Scholar
• Edwards III CK, Martin SW, Seely J, et al. Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases. Adv Drug Deliv Rev 2003;55:1315-36
   PubMed Web of Science ®Google Scholar
• Davis MW, Feige U, Bendele AM, et al. Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I: a clinical update. Ann Rheum Dis 2000;59(Suppl I):i41-3
   PubMed Web of Science ®Google Scholar
• Furst DE, Fleischmann R, Kopp E, et al. A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis. J Rheumatol 2005;32:2303-10
   PubMed Web of Science ®Google Scholar
• Onrust SV, Lamb HM. Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis. BioDrugs 1998;10:397-422
   PubMed Web of Science ®Google Scholar
• Mitoma H, Horiuchi T, Tsukamoto H, et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor a-expressing cells. Arthritis Rheum 2008;58:1248-57
   PubMed Web of Science ®Google Scholar
• St Clair EW, van der Heijde DMFM, Smolen JS. Combination of infliximab andmethotrexate therapy for early rheumatoid arthritis. Arthritis Rheum 2004;50:3432-43
   PubMed Web of Science ®Google Scholar
• Du Pan SM, Gabay C, Finckh. A systematic review of infliximab in the treatment of early rheumatoid arthritis. Ther Clin Risk Manag 2007;3:905-11
   PubMedGoogle Scholar
• Radstake TRDJ, Svenson M, Eijsbouts AM. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical response in rheumatoid arthritis. Ann Rheum Dis 2008 [Epub ahead of print]
   Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF. The PREMIER study: a multicenter, randomized, double-blind clincial trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37
   PubMed Web of Science ®Google Scholar
• Bartelds GM, Wijbrandts CA, Nurmohamed MT. Clincial response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007;66:921-6
   PubMed Web of Science ®Google Scholar
• Melmed GY, Rargan SR, Yasothan U, et al. Certolizumab pegol. Nat Rev Drug Discov 2008;7:641-2
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Schreiber S, Feagan B, et al. CDP870 Crohn's Disease Study Group Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFα, improves health-related quality of life in patients with moderate to severe Crohn's disease. Int J Colorectal Dis 2008;23:289-96
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-38
   PubMed Web of Science ®Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrence IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357:239-50
   PubMed Web of Science ®Google Scholar
• Hutas G. Golimumab, a fully human monoclonal antibody against TNFα. Curr Opin Mol Ther 2008;10:393-406
   PubMed Web of Science ®Google Scholar
• Keystone E, Genovese MC, Klareskog L, et al. Golimumab, a new human anti-TNFα monoclonal antibody, administered subcutaneously every 4 weeks in patients with active rheumatoid arthritis despice methotrexate: week 24 results of the randomized, double-blinded, placebo-controlled, GO-FORWARD study. Ann Rheum Dis 2008;67(Suppl II):185
   Google Scholar
• Tutuncu ZN, Boyle D, Breitmeyer J, et al. AME-527, a fully human monoclonal antibody to TNF-α is well tolerated and reduces signs and symptoms of rheumatoid arthritis (RA). Program and abstracts of the American College of Rheumatology 70th Annual Meeting; 2007:Presentation 936
   Google Scholar
• Gallagher J, Fisher C, Sherman B, et al. A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-α antibody afelimomab in patients with sepsis syndrome. Intensive Care Med 2001;27:1169-78
   PubMed Web of Science ®Google Scholar
• Panacek EA, Marshall JC, Albertson TE, et al. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 2004;32:2173-82
   PubMed Web of Science ®Google Scholar
• Rondon E, Venkataraman R. Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels. Critical Care 2005;9:E20
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Radford-Smith G, et al. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease a randomised, double blind, placebo controlled trial. Gut 2004;53:1485-93
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Lichtenstein G, et al. CDP571, a humanized monoclonal antibody to tumour necrosis factor-α, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2006;23:617-28
   PubMed Web of Science ®Google Scholar
• Ottiger M, Thiel MA, Feige U. Efficient intraocular penetration of topical anti-TNF-α single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer. Invest Ophthalmol Vis Sci 2008 [Epub ahead of print]
   PubMedGoogle Scholar
• Furrer E, Berdugo M, Stella C. Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-α single-chain antibody, upon topical administration to the rabbit eye. Invest Ophthalmol Vis Sci 2008 [Epub ahead of print]
   PubMedGoogle Scholar
• Rice TW, Wheeler AP, Morris PE, et al. Safety and efficacy of affinity-purified, anti-tumor necrosis factor-α, ovine Fab for injection (CytoFab). Crit Care Med 2006;34:2271-81
   PubMed Web of Science ®Google Scholar
• Steed PM, Tansey MG, Zalevsky J, et al. Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science 2003;301:1895-8
   PubMed Web of Science ®Google Scholar
• Zalevsky J, Secher T, Ezhevsky SA, et al. Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. J Immunol 2007;179:1872-83
   PubMed Web of Science ®Google Scholar
• Thoma B, Grell M, Pfizenmaier K, et al. Identification of a 60-kD tumor necrosis factor (TNF) receptor as the major signal transducing component in TNF responses. J Exp Med 1990;172:1019-23
   PubMed Web of Science ®Google Scholar
• Kontermann R, Münkel S, Neumeyer J, et al. A humanized tumor necrosis factor receptor 1 (TNFR1)-specific antgonistic antibody for selective inhibition of tumor necrosis factor (TNF) action. J Immunother 2008;31:225-34
   PubMed Web of Science ®Google Scholar
• Shibata H, Yoshioka Y, Ohkawa A, et al. Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-a antagonist. J Biol Chem 2008;283:998-1007
   PubMed Web of Science ®Google Scholar
• Shibata H, Yoshioka Y, Ohkawa A, et al. The therapeutic effect of TNRF1-selective antagonistic mutant TNF-α in murine hepatitis models. Cytokine 2008;44:229-33
   PubMed Web of Science ®Google Scholar
• Lin J, Zring D, Desai S, et al. TNFα blockade in human diseases: an overview of efficacy and safety.Clin. Immunol 2008;126:13-30
   Web of Science ®Google Scholar
• Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheum 2006;20:757-90
   PubMed Web of Science ®Google Scholar
• Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2006;2:602-11
   PubMedGoogle Scholar
• Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumor necrosis factor treatments in rheumatoid arthritis: meta and exposure adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2008 [Epub ahead of print]
   PubMedGoogle Scholar
• Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra therapies for rheumatoid arthritis: meta-analysis of randomized placebo-controlled trials. Ann Rheum Dis 2008 [Epub ahead of print]
   Google Scholar
• Kroesen S, Widmer AF, Tyndall A, et al. Serous bacterial infections in patients with rheumatoid arthritis under anti-TNF-α therapy. Rheumatology 2003;42:617-21
   PubMed Web of Science ®Google Scholar
• Zimmer C, Beiderlinden M, Peters J. Lethal acute respiratory distress syndrome during anti-TNF-α therapy for rheumatoid arthritis. Clin Rheumatol 2006;25:430-2
   PubMed Web of Science ®Google Scholar
• Schiff MH, Burmester GR, Kent JD. Safety analysis of adalimumab (humira) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:889-94
   PubMed Web of Science ®Google Scholar
• Lin PL, Plessner HL, Voitenok NN, et al. Tumor necrosis factor and tuberculosis. J Investig Dermatol Symp Proc 2007;12:22-25
   PubMed Web of Science ®Google Scholar
• Chen SE, Jin B, Li YP. TNFα regulates myogenesis and muscle regeneration by activating p38 MAPK. Am J Physiol Cell Physiol 2007;292:1660-71
   PubMed Web of Science ®Google Scholar
• Wullaert A, van Loo G, Heyninck K, et al. Hepatic tumor necrosis factor signaling and nuclear factor kB: effects on liver homeostasis and beyond. Endocr Rev 2007;28:365-86
   PubMed Web of Science ®Google Scholar
• Deng X, Lu J, Lehman-McKeeman LD, et al. p38 mitogen-activated protein kinase-dependent tumor necrosis factor-α-converting enzyme is important for liver injury in hepatotoxic interaction between lipopolysaccharide and ranitidine. J Pharmacol Exp Ther 2008;326:144-52
   PubMed Web of Science ®Google Scholar
• Kollias G, Kontoyiannis D, Douni E, et al. The role of TNF/TNFR in organ-specific and systemic autoimmunity: implications for the design of optimized “anti-TNF” therapies. Curr Dir Autoimmun 2002;5:30-50
   PubMedGoogle Scholar
• Marchetti L, Klein M, Schlett K, et al. Tumor necrosis factor (TNF)-mediated neuroprotection against gutamate-induced excitotoxicity is enhanced by N-methyl-D-aspartate receptor activation. Essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase-dependent NF-kappa B pathway. J Biol Chem 2004;279:32869-81
   PubMed Web of Science ®Google Scholar
• McCoy MK, Tansey MG. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation 2008;5:45
   PubMed Web of Science ®Google Scholar
• Balakumar P, Singh M. Anti-tumour necrosis factor-α therapy in heart failure: future directions. Basic Clin Pharmacol Toxicol 2006;99:391-7
   PubMed Web of Science ®Google Scholar
• Szymkowski DE. Creating the next generation of protein therapeutics through rational drug design. Curr Opin Drug Discov Dev 2005;8:590-600
   PubMed Web of Science ®Google Scholar
• McCoy MK, Martinez TN, Ruhn KA, et al. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J Neurosci 2006;26:9365-75
   PubMed Web of Science ®Google Scholar
• Sethi G, Sung B, Aggarwal BB. TNF: a master switch for inflammation to cancer. Front Biosci 2008;13:5094-107
   PubMed Web of Science ®Google Scholar